BACKGROUND AND PURPOSE: 4D-CT is a novel method of multiphase CT imaging. When used to localize parathyroid adenomas and hyperplasia, this technique may allow for more robust diagnostic accuracy than traditional sonography and nuclear scintigraphy techniques. The purpose of our study is to assess the accuracy of 4D-CT for localizing pathologically proved parathyroid adenomas and hyperplasia found during surgery.
D
irected parathyroidectomy is a minimally invasive surgical technique for parathyroid adenoma resection. When combined with intraoperative parathyroid hormone assay, this technique demonstrates high cure rates, low complications rates, and avoids both general anesthesia and overnight hospital stays associated with classic bilateral neck exploration. 1 Critical to the success of a directed technique is preoperative localization of the abnormal parathyroid gland. 2 Traditional imaging modalities such as sonography and sestamibi-SPECT demonstrate high specificity when concordant, but suboptimal sensitivity in most hands. 3 In addition, ectopic parathyroid adenomas, sometimes located in sonographically inaccessible regions such as the mediastinum, benefit from evaluation with a cross-sectional imaging technique. 4 The purpose of our study is to assess the accuracy of 4D-CT for localizing pathologically proven parathyroid adenomas and hyperplasia found at surgery. 4D-CT is a novel method of multiphase CT imaging. [5] [6] [7] [8] This technique utilizes the principles of altered arterial enhancement and washout that guided early angiographic detection of parathyroid adenomas. 9, 10 Our hypothesis is that preoperative 4D-CT can accurately localize the abnormal parathyroid gland found at surgery. 4D-CT may allow for more robust diagnostic accuracy than traditional sonography and nuclear scintigraphy techniques. 5 Furthermore, 4D-CT facilitates the detection of coexistent thyroid and mediastinal pathology, and may provide superior accuracy in patients with prior neck surgery.
7,8

Materials and Methods
Patients
A waiver of informed of consent was obtained from our institutional review board and was performed in a fashion consistent with the Health Insurance Portability and Accountability Act. We began performing 4D-CT studies at our institution in January 2009 and reviewed all such studies performed at our institution between January 2009 and March 2011 for clinically suspected parathyroid hyperplasia. Inclusion criterion was availability of final surgical pathology. In cases of single-gland disease, a pathologic diagnosis of "parathyroid hyperplasia" was presumed to represent a parathyroid adenoma. This is because, while a specimen may have morphologic features of a parathyroid adenoma, the pathologist cannot exclude the possibility of hyperplasia if only 1 gland was submitted for evaluation. No cases were excluded. Patient demographic data, including age, sex, BMI, and preoperative and postoperative PTH levels, were obtained. For purposes of precise gland localization, lesions were categorized into 4 quadrants.
CT Technique
All examinations were performed with a LightSpeed 16-or 64-detector row CT scanner (GE Healthcare, Milwaukee, Wisconsin) with a rotation time of 600 ms, scan field of view of head, display field of view of 18 cm, pitch of 0.984:1, tube voltage of 120kVp, and automatic exposure control (Smart mA algorithm, GE Healthcare) with a range from 150 -300 mA and noise index of 14 at 1.25-mm section thick-ness. Imaging extended from the carina to the bottom of the mandibular teeth in a caudal to cranial direction, in a plane parallel to the hard palate. Each examination included a scout scanogram, noncontrast acquisition, and multiphase imaging following the administration of intravenous contrast.
Iohexol 300 (Omnipaque; GE Healthcare) nonionic iodinated contrast was administered at a dose of 2 mL per kg patient weight to a maximum total of 120 mL. Intravenous infusion rate was 4 mL per second via an 18-gauge catheter.
The diagnostic multiphase CT was acquired at 1.25-mm section thickness. The helical postcontrast sequence was obtained 25 seconds after the start of intravenous contrast administration. Following a subsequent 30-second delay, a delayed phase sequence was acquired. Axial, sagittal, and coronal 2.5-mm reformations were generated.
Image Analysis
Images were reviewed prospectively on a PACS workstation by a single attending neuroradiologist with over 20 years of experience in head and neck imaging, and a certificate of added qualification in neuroradiology. Biochemical information was available at the time of interpretation, including the preoperative PTH levels. Images were reviewed and determined to be positive if a soft tissue lesion in the expected location of parathyroid tissue (orthotopic or ectopic) demonstrated early arterial enhancement and qualitatively appreciable contrast washout on early or late delayed images. The radiology report provided a descriptive location for our referring surgeons, with anatomic landmarks. Any coexistent pathology that was deemed to potentially alter patient management was also noted.
Statistical Analysis
SAS version 9.2 (SAS Institute, Cary, North Carolina) was used for all statistical analysis. Categoric variables are presented as frequencies and percents, while continuous variables are presented as means and standard deviations. To determine how well 4D-CT performs in preoperative localization, we used diagnostic accuracy measures comparing 4D-CT to the "gold standard" of surgical pathology. Correct localization of the lesions was ascertained by using side and quadrant of the neck. Diagnostic accuracy measures for both side and quadrant location were determined by using sensitivity, specificity, PPV, NPV, and accuracy, with corresponding 95% confidence intervals calculated by using the exact binomial distribution method.
Results
All studies were performed in patients with elevated PTH and a clinical diagnosis of primary hyperparathyroidism. A total of 42 4D-CT studies were performed over the study period. Of these, 35 patients went to surgery with final pathology available and were included in the analysis. The remaining 7 patients were lost to follow-up or refused surgery. No cases were negative for parathyroid hyperplasia on surgical exploration. Table 1 displays the descriptive statistics for our cohort. Of the 35 cases, 32 cases of parathyroid adenoma or multigland hyperplasia were detected by using 4D-CT (sensitivity ϭ 91%, 95% CI 77%, 98%). To calculate diagnostic accuracy of 4D-CT to correctly determine side and quadrant location of the lesions, we looked at the 32 cases that were positive by both pathology and 4D-CT. Of these 32 cases, 5 cases were removed because multiple glands were involved. The final single-gland dataset contained 27 cases. Table 2 displays the distribution of the pathology and 4D-CT findings from these 27 individuals. We then determined the diagnostic accuracy of 4D-CT to correctly lateralize the adenoma found at surgery. For diagnostic accuracy, pathology was treated as the gold standard. 4D-CT test results were correlated to pathology, and each CT result was evaluated and classified as true-positive, true-negative, false-positive, or false-negative in terms of the ability to accurately predict laterality (right versus left). It is important to note that false-positives and false-negatives were equally weighted. The sensitivity of 4D-CT to correctly identify a right-sided adenoma was 92% (61.5%, 99.8%), and the specificity of 4D-CT to correctly identify a left-sided adenoma was 93.3% (68.1%, 99.8%). The overall accuracy of 4D-CT to correctly identify adenoma side (assuming 4D-CT was positive) was 93% (76%, 99%). Table 3 presents all diagnostic accuracy measures for 4D-CT lateralization.
We also evaluated the ability of 4D-CT to precisely localize an adenoma. For this analysis, we looked at the 25 patients with single-gland disease that was correctly lateralized by 4D-CT. Again, pathology was treated as the criterion standard, and 4D-CT results were classified as true-positive, true-negative, false-positive, or false-negative in terms of the ability to accurately predict location (superior versus inferior). As before, false-positives and false-negatives are equally weighted. The sensitivity of 4D-CT to correctly determine superior adenoma quadrant location was 85.7% (57.2%, 98.2%), and the specificity to correctly determine inferior adenoma quadrant location was 100% (71.5%, 100%). The overall accuracy of 4D-CT to correctly identify precise adenoma location (assuming 4D-CT was positive for adenoma and correctly identified side) was 92% (74%, 99%). Table 4 provides all diagnostic accuracy for 4D-CT quadrant localization. Last, we looked at patients with multigland disease (including 4-gland hyperplasia and double adenomas). By pathology, 7 patients in total were determined to have multigland involvement. Of these, 2 (29%) were called negative for any parathyroid lesion on 4D-CT. We looked at diagnostic accuracy for multigland disease, both including and excluding patients called negative by 4D-CT. As before, pathology was treated as the criterion standard, with true-positives defined as those that CT correctly called lesions at multiple locations, false-positives as those that CT incorrectly called not multigland (but are truly multigland), true-negatives as those that CT correctly called not multigland, and false-negatives as those that CT incorrectly called multigland (but are truly not multigland). Looking at all 35 patients, 4D-CT has a low sensitivity of 42.9% (9.9%, 81.6%) in detecting multigland dis- ease. However specificity to rule out a multigland disease in this population was perfect (specificity ϭ 100%, 95% CI, 87.7%, 100%). Looking at the 32 patients in whom both pathology and 4D-CT were positive, 4D-CT had a slightly higher sensitivity of 60% (CI, 14.7%, 94.7%) for detecting multigland disease. As before, the specificity of 4D-CT in ruling out multigland disease in this population was perfect (specificity ϭ 100%, 95% CI, 87.2%, 100%). Table 5 displays the diagnostic accuracy of 4D-CT in detecting multigland disease, including those patients called negative by 4D-CT. Discussion 4D-CT demonstrated high accuracy for the determination of both lesion side and quadrant location for single-gland disease. Our series suggests that 4D-CT agrees with the pathology findings in most of the cases and is a reliable choice for parathyroid adenoma detection. Importantly, 4D-CT accurately lateralized single-gland adenomas in 93% of cases, allowing the surgeon to perform a unilateral neck dissection with associated decreased morbidity and length of hospital stay. The ability to accurately lateralize the side of disease is a commonly used end point in parathyroid imaging because it enables a directed surgical approach. By comparison, sonography has a cited sensitivity for lateralization ranging from 57% to 86%. 5, 11 4D-CT appears to hold potential for detection of multi- gland disease. Although this technique demonstrated suboptimal sensitivity of 44% in patients with multigland disease, it was 100% specific for ruling out multigland disease, as no cases that were thought to have multigland disease by 4D-CT had single-gland adenomas at pathology. These results compare favorably to those reported for sonography and sestamibi techniques. A review by Sugg et al, 12 including 23 patients with multigland disease, found that the combination of sonography and sestamibi imaging correctly predicted multigland disease in 30% of patients, incorrectly called single-gland disease in 30%, did not identify abnormal parathyroid glands in 30%, and yielded discordant results in 10%. In our cohort, 2 of the 3 false-negatives for parathyroid lesion detection were patients with multigland disease. Multigland lesions are particularly challenging to detect prospectively, likely related to the small lesion size. We would further posit, as other authors have suggested, that in the case of a negative 4D-CT examination, there is presumed multigland disease. Importantly, some authors suggest a nonselective operative approach in cases of negative or discordant imaging studies due to the increased likelihood of multigland pathology. 2, 13 Unique angiographic and perfusion characteristics of parathyroid adenomas were described by Doppman and others in the 1970s, and used to identify abnormal hypervascular glands with preoperative digital subtraction angiography.
9,14 A characteristic "blush" has been described following the injection of intra-arterial contrast, indicating the presence of an abnormal gland that is hypervascular compared with normal thyroid and parathyroid tissue. Similar principles are applied to contrast-enhanced CT, where hyperenhancement, location, and size are important discriminators in detecting parathyroid adenomas. 4 4D-CT appears to further enhance detection, with the advantages of noncontrast imaging to distinguish the gland from surrounding thyroid tissue, early postcontrast imaging to assess for a hypervascular gland, and delayed postcontrast imaging to detect regions of altered enhancement and abnormal contrast retention.
It is important to be cognizant of the radiation dose delivered with CT, particularly multiphase CT. We use dose reduction techniques with 4D-CT, as described by Welling et al, 8 including automatic tube current modulation and limiting the superior field of view to the mandibular teeth. Despite these techniques, 4D-CT delivers a significant radiation dose. Calculated CTDI vol measurements range from 19.8 mGy (at 150mA) to 39.7 mGy (at 300 mA) per phase of imaging. These parameters are comparable with recently reported CTDI vol values for neck CT ranging from 23.0 to 34.7 mGy. 15 We have chosen not to exclude the noncontrast examination, as we think it provides important diagnostic information, particularly in its ability to show attenuation differences in lesions contiguous with the thyroid gland. The risk-benefit discussion must weigh the cost, morbidity, and risk of formal neck exploration with the exposure from 4D-CT. The examination will likely only require performance on a single occasion.
There are several limitations to our study. First, this study is a retrospective review and was not designed to make a direct prospective comparison of the accuracy of sonography, sestamibi, and 4D-CT imaging for the detection of parathyroid pathology. Second, there is a selection bias for cases of ectopic and multigland disease because these are more difficult to diagnose on traditional imaging modalities and thus more likely to progress to 4D-CT imaging. Our patient population may be skewed by this factor, with a relatively higher proportion of these subtypes of adenomas. Third, although the technique of 4D-CT at our institution has been performed with high accuracy, variability in diagnostic accuracy may occur across institutions, secondary to interpreter experience and study technique.
Nonetheless, our series demonstrates that 4D-CT is a valuable tool for appropriate operative planning. 4D-CT also shows a higher sensitivity and accuracy than commonly cited for sonography or sestamibi imaging. We believe the accuracy of this technique is particularly impressive when considering the patients referred for 4D-CT frequently had equivocal or indeterminate findings on prior sonography and sestamibi-SPECT studies. The multiplanar reconstruction capabilities provide beneficial spatial information for optimal operative planning and intervention.
Conclusions
4D-CT demonstrated a high diagnostic accuracy for singlegland disease in our cohort and high specificity in multigland disease. Importantly, 4D-CT predicted the correct side of single-gland adenomas in 93% of cases, allowing the surgeon to utilize a directed operative approach. Potential difficulties with the technique include radiation exposure and necessity of iodinated contrast media. 
